• arclein
The latest in a new class of “super” cholesterol drugs, CETP inhibitors, now in the drug approval pipeline from Merck (anacetrapib) burst into the news recently with exclamations from typically restrained scientists. Data on this new drug was recently published in the New England Journal of Medicine and presented at the American Heart Association conference in Chicago.
Watch Streaming Broadcast Live:
LRN.fm
DLive
Live Chat Telegram
Share this page with your friends
on your favorite social network: